期刊
FRONTIERS IN IMMUNOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.837457
关键词
monoclonal antibodies; antibody-drug conjugates; bispecific T cell engagers; genetic modification; engineered T cells; CAR-T cells; CAR-NK cells
类别
资金
- Fondazione AIRC IG [20312, PRIN 2017WC8499_004]
Surgical resection, chemotherapy, and radiotherapy have been the primary cancer treatments for a long time. Recently, immune checkpoint inhibitors and adoptive cell therapies have emerged as promising alternatives. These therapies aim to activate and utilize the patient's immune system to fight against cancer cells, and have shown remarkable results.
Surgical resection, chemotherapy and radiotherapy were, for many years, the only available cancer treatments. Recently, the use of immune checkpoint inhibitors and adoptive cell therapies has emerged as promising alternative. These cancer immunotherapies are aimed to support or harness the patient's immune system to recognize and destroy cancer cells. Preclinical and clinical studies, based on the use of T cells and more recently NK cells genetically modified with chimeric antigen receptors retargeting the adoptive cell therapy towards tumor cells, have already shown remarkable results. In this review, we outline the latest highlights and progress in immunotherapies for the treatment of Diffuse Large B-cell Lymphoma (DLBCL) patients, focusing on CD19-targeted immunotherapies. We also discuss current clinical trials and opportunities of using immunotherapies to treat DLBCL patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据